Document is current
Any future updates will be listed below
-
Authors
Mann, Jacqueline E.
Hasson, Nitzan
Su, David G.
Adeniran, Adebowale J.
Smalley, Keiran S. M.
Djureinovic, Dijana
Jilaveanu, Lucia B.
Schoenfeld, David A.
Kluger, Harriet M.
-
Funding
Funding for this research was provided by:
NIH (1T32AI155387-01A1, 1R01CA269349)
- License Information
-
More Information
Article History
Received: 21 May 2024
Accepted: 5 July 2024
First Online: 6 August 2024
Declarations
:
: H.M.K. holds Consulting or Advisory Roles with Iovance Biotherapeutics, Merck, Clinigen Group, Bristol Myers Squibb, ChemoCentryx, Signatera, Gigagen, GI Reviewers, Seranova Bio, Pliant, Eisai, Invox, Werewolf Pharma, has received research funding from Merck (Inst), Bristol Myers Squibb (Inst), Apexigen (Inst), and has received travel, accomodations, or expenses from Apexigen. No other potential competing interests were reported.
